MedTrace Logo

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

NCT00002475 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-07-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.

Conditions

Interventions

BIOLOGICAL

allogeneic tumor cell vaccine

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

recombinant interferon alfa

BIOLOGICAL

recombinant interferon gamma

BIOLOGICAL

sargramostim

DRUG

cyclophosphamide

Sponsors & Collaborators

  • St. Vincent Medical Center - Los Angeles

    lead OTHER

Principal Investigators

  • Charles L. Wiseman, MD, FACP

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-04-30
Primary Completion
2007-12-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002475 on ClinicalTrials.gov